News and Media

AMDI donates Remdesivir Injection to MOH for fight against COVID-19 – November 4, 2020

ANSA McAL Distribution Inc. (AMDI) on Wednesday November 4, 2020 delivered 100 vials of Remdesivir to the Ministry of Health as a donation to continue the fight against the COVID-19 Pandemic.

At the simple presentation ceremony held at the Ministry of Health on Brickdam Street, Managing Director of AMDI, Troy Cadogan noted that, “ANSA McAL Distribution Inc., has long been cognizant of its’ Corporate Social Responsibility, and has donated Trinchloro bleach through the Rotary Club of Guyana since March. However as one of the leading distributors in Guyana, AMDI has partnered with one of its suppliers to donate 100 units of Remdesivir 100mg Injection.

“The donation of this drug will provide a powerful tool in the government’s arsenal to help in their fight against some of the debilitating symptoms of COVID-19, that can occur in some cases,” Cadogan shared.

Minister of Health, Dr. Frank Anthony accepted the kind gesture and highlighted that it is such efforts by corporate Guyana that will aid in the fight against COVID-19.

Dr. Anthony also noted that the Remdesivir Injection is a “powerful component” in the fight against the virus but also urged AMDI to continue to spread the word on COVID-19 protocols that includes the wearing of masks, social distancing and hand sanitizing.

Managing Director of AMDI, Troy Cadogan (left) chats with Minister of Health, Dr. Frank Anthony (centre) and Permanent Secretary of the Ministry of Health, Malcolm Watkins

Meanwhile, AMDI also committed to donating another 100 vials of the injection by this coming weekend with the total cost of the 200 vials amounting to just over seven million dollars.


Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models. Early clinical studies have shown clinically meaningful differences and reductions in some clinical parameters in patients.